Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	43.47B
Revenue (ttm)	14.61B
Net Income (ttm)	672.53M
Shares Out	300.00M
EPS (ttm)	2.24
PE Ratio	64.64
Forward PE	n/a
Dividend	0.13 (0.08%)
Ex-Dividend Date	Nov 12, 2025

Volume	2,927,359
Average Volume	1,076,058
Open	161.60
Previous Close	161.00
Day's Range	144.90 - 161.80
52-Week Range	100.50 - 224.00
Beta	0.96
RSI	30.16
Earnings Date	Mar 3, 2026

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, tra...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 619
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2024, IST:GENIL's revenue was 14.74 billion, an increase of 25.25% compared to the previous year's 11.77 billion. Earnings were 148.68 million, a decrease of -77.35%.